Given the evidence that supports RAC1 activity inhibition in various tumour types and its elevated expression in MOC, there may be potential in not only targeting this receptor with theranostic agents, but also in exploring agents to inhibit it in treatment-resistant and advanced MOC with a view of improving sensitivity to current chemotherapy agents. Here, RAC1 is linked to neoplasm.